
    
      Yangxue Qingnao pills is a traditional Chinese herbal medicine, which is composed of
      Angelicae Sinensis Radix , Chuanxiong Rhizoma , Paeoniae Radix Alba, Rehmannia glutinosa,
      Uncaria macrophylla Wall, Caulis spatholobi, Spica Prunellae, Catsia tora Linn , Mater
      Margarita, Corydalis ambigua and Asarum sieboldii. The function of Yangxue Qingnao pills is
      nourishing blood and calming liver, promoting blood circulation and dredging collaterals in
      Chinese traditional medicine theory. This study is a 48-weeks, multicenter, randomized,
      double-blind, parallel controlled phase II trial being carried out in China. The study
      population includes mild to moderate Alzheimer's disease (planned a total of 216) aged 65-85
      in both gender. Participants will be randomly allocated to Yangxue Qingnao pills high dose
      group (7.5 g per time,2 times per day) ; and Yangxue Qingnao pills low dose group (5 g per
      time,2 times per day), or placebo group for a 48-weeks double-blind treatment period. The
      primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale-
      Cognition Subscale (ADAS-cog) and the clinical dementia rating scale. The secondary outcomes
      are changes from baseline in the Mini-Mental State Examination(MMSE), Alzheimer's Disease
      Cooperative Study-Activities of Daily Living scale (ADCS-ADL/24) and Neuropsychiatric
      Inventory. Besides, the blood biomarkers including Aβ42, Aβ40, T-tau, P-tau181, NfL, TOM1,
      IL-1R1,IL-1b, IL-6, IL-8, TNF-a, FB, FH, sCR1, MCP-1, eotaxin-1, Ach, ChEI and the
      hippocampal volume on MRI. Safety is being assessed by observing side effects and adverse
      reaction during the entire treatment period. Statistical analysis will be conducted according
      to per-protocol population and intend-to-treat population and the safety will be analyzed in
      safety set.
    
  